| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Remodelin is a novel, selective and potent acetyl-transferase NAT10 inhibitor that is cell-permeable and stable analog of CPTH2. Remodelin inhibits acetyl-transferase NAT10, a nuclear N-acetyltransferase involved in stabilization of microtubules. Remodelin was found to correct cell defects associated with progeria, restoring and improving nuclear shape and reducing the DNA damage believed to be associated with mutations in the gene for laminin A. Remodelin can improve nuclear architecture, chromatin organization, and fitness of both human lamin A/C-depleted cells and HGPS-derived patient cells, and decrease markers of DNA damage in these cells. Remodelin is a useful chemical tool to study how NAT10 affects nuclear architecture and suggest alternative strategies for treating laminopathies and aging.
| Targets |
NAT10 (N-acetyltransferase 10)
|
|---|---|
| ln Vitro |
Both AR-positive and AR-negative prostate cancer cells exhibit dose-dependent inhibition of NAT10 function and cell proliferation when exposed to remodelin (10–40 μM) for 1–7 days [2]. In prostate cancer cells, remodelin (20 μM, 24 hours) inhibits NAT10 and slows down DNA replication [2]. In LmnaG609G/G609G fibroblasts, remodelin (1 μM, 7 days) decreases nuclear morphological abnormalities and promotes genome stability [3].
|
| ln Vivo |
In a tumor xenograft nude mouse model, remodelin (2 or 20 mg/kg, intraperitoneally, once every two days for 4 weeks) dramatically slows the growth of AR-negative prostate cancer [2]. Remodelin (100 mg/kg, oral) prolongs healthspan in the LmnaG609G/G609G mouse model of premature aging syndrome (HGPS) by a significant amount and suppresses NAT10 [3]. In mice, remodelin (5 mg/kg, oral) had an oral bioavailability (F%) of 43.5% and a T1/2 of 1.81 hours [3]. Mouse remodelin pharmacokinetic parameters: route dose (mg/kg), T1/2 (h), Tmax (h), Cmax (ng/mL), AUC0-t (ng/h/mL), AUC0-Ɲ (ng/h/mL), MRT_last (h), F(%) po 5 1.81 0.25 409 235 259 0.84 43.5%
|
| Enzyme Assay |
Lysine acetyltransferase (KAT) assay.[1]
The KAT assay was performed using the Fluorescent HAT Assay kit using NAT10 purified from HEK293 cells and 5 μg of purified MAP enriched Tubulin Porcine as a substrate. Remodelin and clickable molecule 2 were used at 50 μM. [1] Circular Dichroism Spectroscopy.[1] CD experiments were performed using a Chirascan Circular Dichroism Spectrophotometer. 200 μl of purified FLAG-NAT10 at a final concentration of 10 μM in TBS + 0.1 % NP-40 was placed in a quartz cuvette with an optical path length of 1 mm, transferred to the spectrophotometer. CD scans were recorded at 25°C over the wavelength range of 180 to 350 nm with a 1s response time, 1 nm pitch and 1.5-nm bandwidth. Compound 1 solubilized in DMSO was added and the solution was incubated for 5 min before recording scans. CD spectra were buffer subtracted, zero corrected at 300 nm and normalized (Molar ellipticity θ is quoted in 105 deg cm2 dmol−1). |
| Cell Assay |
Cell Proliferation Assay[2]
Cell Types: Prostate cancer cell lines VCaP, PC3, and DU145 Tested Concentrations: 0,10,20,40 μM Incubation Duration: 1,2,7 days Experimental Results: Inhibited NAT10 and suppressed the growth of both AR- positive and AR-negative prostate cancer cells. Displayed Dramatically diminished cell proliferation activity over time, compared to the control group. diminished colony formation ability with a dose-dependent manner. Immunofluorescence[2] Cell Types: Prostate cancer cell lines VCaP, PC3, and DU145 Tested Concentrations: 0,10,20,40 μM Incubation Duration: 24 hrs (hours) Experimental Results: demonstrated a significant decrease in both the positive labeling rate and the fluorescence intensity compared to the control group. Dramatically decreased both the staining foci of IdU and the staining foci of CldU compared to control group. Western Blot Analysis[3] Cell Types: Skin fibroblasts from LmnaG609G/G609G and wildtype (WT) littermates Tested Concentrations: 1 μM Incubation Duration: 7 days Experimental Results: diminished the higher level of the DNA dou |
| Animal Protocol |
Animal/Disease Models: PC-3 cells tumor xenograft model in nude athymic BALB/c nu/nu (nude) mice[2]
Doses: 2 or 20 mg/ kg Route of Administration: intraperitoneal (ip)injection, once every two days for 4 weeks Experimental Results: Dramatically decreased AR-negative prostate cancer tumor growth. In the high-dose group, xenograft tumor weight at the endpoint was much smaller than that in the low- dose group. Animal/Disease Models: LmnaG609G/G609G hutchinson-gilford progeria syndrome (HGPS) mouse model[3] Doses: 100 mg/kg Route of Administration: po (oral gavage), daily schedule for 3 weeks of age onward, until the end-point Ameliorated age-dependent weight loss. Experimental Results: Ameliorated cardiac pathology. Led to the dramatic amelioration of HGPS cardiac pathologies, including reduction of adventitial fibrosis of the aorta, rescue of vascular smooth muscle cell loss, and salvage of smooth muscle actin (SMA) loss , both in the aorta and the coronary arteries. Animal/Disease Models: WT Mice (pharmacokinetic/PK assay)[3] Doses: 5 mg/kg Route of Administration: Oral gav |
| References |
|
| Molecular Formula |
C15H14N4S
|
|
|---|---|---|
| Molecular Weight |
282.36
|
|
| Exact Mass |
282.093
|
|
| Elemental Analysis |
C, 63.81; H, 5.00; N, 19.84; S, 11.35
|
|
| CAS # |
949912-58-7
|
|
| Related CAS # |
Remodelin hydrobromide;1622921-15-6
|
|
| PubChem CID |
44442376
|
|
| Appearance |
Off-white to light yellow solid
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
498.9±47.0 °C at 760 mmHg
|
|
| Flash Point |
255.5±29.3 °C
|
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
|
| Index of Refraction |
1.702
|
|
| LogP |
2.16
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
20
|
|
| Complexity |
397
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
N#CC1C=CC(C2=CSC(N/N=C3/CCCC/3)=N2)=CC=1
|
|
| InChi Key |
XAEJIFARBQJLML-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C15H14N4S/c16-9-11-5-7-12(8-6-11)14-10-20-15(17-14)19-18-13-3-1-2-4-13/h5-8,10H,1-4H2,(H,17,19)
|
|
| Chemical Name |
4-[2-(2-cyclopentylidenehydrazinyl)-4-thiazolyl]-benzonitrile
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5416 mL | 17.7079 mL | 35.4158 mL | |
| 5 mM | 0.7083 mL | 3.5416 mL | 7.0832 mL | |
| 10 mM | 0.3542 mL | 1.7708 mL | 3.5416 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Inhibiting NAT10 activity by Remodelin mediates nuclear shape rescue of LMNA depleted cells. Science. 2014 May 2;344(6183):527-32. |
Remodelin targets NAT10 to improve nuclear shape and fitness of HGPS cells. Science. 2014 May 2;344(6183):527-32. |
Inhibiting NAT10 acetyltransferase activity modifies microtubule organisation to rescue nuclear shape defects. Science. 2014 May 2;344(6183):527-32. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
